Adlai Nortye Ltd. American Depositary Shares Total Assets
Adlai Nortye Ltd. American Depositary Shares total assets. Based on the latest financial reports, Adlai Nortye Ltd. American Depositary Shares (ANL) holds total assets worth $34.43 Million USD as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Also see Adlai Nortye Ltd. American Depositary Sh market cap and net worth for the company's overall valuation and market capitalisation.
Total Assets of Adlai Nortye Ltd. American Depositary Shares (2019–2025)
Total assets of Adlai Nortye Ltd. American Depositary Shares from 2019 to 2025. This chart illustrates how Adlai Nortye Ltd. American Depositary Shares's total assets have evolved over time, based on quarterly financial data. See current stock price of Adlai Nortye Ltd. American Depositary Sh for real-time trading data and today's change.
Adlai Nortye Ltd. American Depositary Shares - Asset Composition Analysis
Adlai Nortye Ltd. American Depositary Shares Total Assets Breakdown (December 2025)
Adlai Nortye Ltd. American Depositary Shares total assets breakdown as of December 2025. Adlai Nortye Ltd. American Depositary Shares's total assets of $34.43 Million consist of 78.1% current assets and 21.9% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 69.1% |
| Accounts Receivable | $1.39 Million | 4.0% |
| Inventory | $0.00 | 0.0% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $19.00K | 0.1% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2019–2025)
This chart illustrates how Adlai Nortye Ltd. American Depositary Shares's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. Explore Adlai Nortye Ltd. American Depositary Sh current assets vs equity to assess how much short-term liquidity the company maintains relative to its equity base.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Adlai Nortye Ltd. American Depositary Shares's current assets represent 78.1% of total assets in 2025, an increase from 59.5% in 2019.
- Cash Position: Cash and equivalents constituted 69.1% of total assets in 2025, up from 55.7% in 2019.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, a decrease from 1.0% in 2019.
- Asset Diversification: The largest asset category is accounts receivable at 4.0% of total assets.
Adlai Nortye Ltd. American Depositary Shares Competitors by Total Assets
Key competitors of Adlai Nortye Ltd. American Depositary Shares based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN
|
USA | $11.72 Billion |
|
HLB Co. Ltd
KQ:028300
|
Korea | ₩925.44 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.99 Billion |
|
Shanghai Medicilon Inc
SHG:688202
|
China | CN¥2.88 Billion |
|
Blue Jet Healthcare Limited
NSE:BLUEJET
|
India | Rs16.41 Billion |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767
|
China | CN¥2.49 Billion |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197
|
China | CN¥725.73 Million |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880
|
China | CN¥3.67 Billion |
Adlai Nortye Ltd. American Depositary Shares - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 0.65 | 1.41 | 0.21 |
| Quick Ratio | 0.65 | 1.41 | 0.21 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $-14.74 Million | $18.70 Million | $-246.35 Million |
Adlai Nortye Ltd. American Depositary Shares - Advanced Valuation Insights
This section examines the relationship between Adlai Nortye Ltd. American Depositary Shares's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 82.76 |
| Latest Market Cap to Assets Ratio | 16.29 |
| Asset Growth Rate (YoY) | -51.7% |
| Total Assets | $34.43 Million |
| Market Capitalization | $560.92 Million USD |
Valuation Analysis
Premium Asset Valuation: The market values Adlai Nortye Ltd. American Depositary Shares's assets at a significant premium (16.29x), suggesting investors see substantial growth potential or unique competitive advantages.
Significant Asset Reduction: Adlai Nortye Ltd. American Depositary Shares's assets decreased by 51.7% over the past year, potentially indicating divestiture, restructuring, or challenging business conditions.
Annual Total Assets for Adlai Nortye Ltd. American Depositary Shares (2019–2025)
The table below shows the annual total assets of Adlai Nortye Ltd. American Depositary Shares from 2019 to 2025.
| Year | Total Assets | Change |
|---|---|---|
| 2025-12-31 | $34.43 Million | -51.69% |
| 2024-12-31 | $71.27 Million | -45.26% |
| 2023-12-31 | $130.19 Million | +79.34% |
| 2022-12-31 | $72.59 Million | -44.87% |
| 2021-12-31 | $131.69 Million | +258.40% |
| 2020-12-31 | $36.74 Million | +240.10% |
| 2019-12-31 | $10.80 Million | -- |
About Adlai Nortye Ltd. American Depositary Shares
Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rect… Read more